Prescription drug · ANDA
Podofilox NDC 0574-0621
Podofilox 5 mg/g · Gel · Topical · Padagis US LLC
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 0574-0621-05 | 0057406210500574062105 | 3.5 g in 1 TUBE, WITH APPLICATOR (0574-0621-05)Marketed from Dec 13, 2023 |
How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Podofilox
- Generic name (nonproprietary)
- podofilox
- Active ingredients
- Podofilox — 5 mg/g
- Dosage form
- Gel
- Route
- Topical
- Labeler
- Padagis US LLCNDC labeler code 0574
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 211871
- Marketing start
- Listing expires
- Other FDA classes
- Decreased Mitosis (Physiologic effect)
- Identifiers
- Product ID 0574-0621_d2e70c5e-d4a9-4295-9eff-517ffb974e61SPL ID d2e70c5e-d4a9-4295-9eff-517ffb974e61SPL set ID d2e70c5e-d4a9-4295-9eff-517ffb974e61RxCUI 312466UNII L36H50F353
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Topical products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N400574062105followed by a unit qualifier and the quantityPackage 00574-0621-05. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE Podofilox gel is indicated for the topical treatment of anogenital warts (external genital warts and perianal warts). This product is not indicated in the treatment of mucous membrane warts (see PRECAUTIONS ). Diagnosis Although anogenital warts have a characteristic appearance, histopathologic confirmation should be obtained if there is any doubt of the diagnosis. Differentiating warts from squamous cell carcinoma and "Bowenoid papulosis" is of particular concern. Squamous cell carcinoma may also be associated with human papillomavirus which should not be treated with podofilox gel.
Excerpt only. Read the full label for complete information.
About NDC 0574-0621
- What is NDC 0574-0621?
- 0574-0621 is the product NDC for Podofilox, Podofilox 5 mg/g gel, listed with the FDA by Padagis US LLC. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Podofilox.
- What is the active ingredient?
- Podofilox.
- Who is the labeler?
- Padagis US LLC, NDC labeler code 0574. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Podofilox?
- 1 other product NDC are listed under this name. See all Podofilox NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Podofilox products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Podofilox | Podofilox 5 mg/mL | SolutionTopical | Padagis US LLC | 0574-0611 | 00574-0611-05 |